lactic acid has been researched along with Craniopharyngioma in 3 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Craniopharyngioma: A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations. (From Joynt, Clinical Neurology, 1998, Ch14, p50)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Poly(lactic-co-glycolic acid) microspheres loaded with imatinib mesylate has been developed as a new therapeutic strategy to prevent craniopharyngioma recurrence." | 7.79 | Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis. ( Akgun, E; Avsar, T; Baysal, K; Karal-Yilmaz, O; Kilic, T; Kukut, M; Ozkan, A, 2013) |
| "Poly(lactic-co-glycolic acid) microspheres loaded with imatinib mesylate has been developed as a new therapeutic strategy to prevent craniopharyngioma recurrence." | 3.79 | Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis. ( Akgun, E; Avsar, T; Baysal, K; Karal-Yilmaz, O; Kilic, T; Kukut, M; Ozkan, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karal-Yilmaz, O | 1 |
| Ozkan, A | 1 |
| Akgun, E | 1 |
| Kukut, M | 1 |
| Baysal, K | 1 |
| Avsar, T | 1 |
| Kilic, T | 1 |
| Arefyeva, IA | 1 |
| Semenova, JB | 1 |
| Zubairaev, MS | 1 |
| Kondrasheva, EA | 1 |
| Moshkin, AV | 1 |
| Cavallo, LM | 1 |
| Messina, A | 1 |
| Esposito, F | 1 |
| de Divitiis, O | 1 |
| Dal Fabbro, M | 1 |
| de Divitiis, E | 1 |
| Cappabianca, P | 1 |
1 trial available for lactic acid and Craniopharyngioma
| Article | Year |
|---|---|
Skull base reconstruction in the extended endoscopic transsphenoidal approach for suprasellar lesions.
Topics: Biocompatible Materials; Bone Substitutes; Cranial Fossa, Posterior; Craniopharyngioma; Dura Mater; | 2007 |
2 other studies available for lactic acid and Craniopharyngioma
| Article | Year |
|---|---|
Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Craniopharyngioma; Imatinib | 2013 |
Analysis of fluid in craniopharyngioma-related cysts in children: proteins, lactate and pH.
Topics: Adolescent; Albumins; Blood-Brain Barrier; Brain Diseases; Brain Neoplasms; Child; Child, Preschool; | 2002 |